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Abstract
Human amniotic epithelial cells (hAEC) have stem cell-like features and immunomodulatory properties. Here we show that
hAEC significantly suppressed splenocyte proliferation in vitro and potently attenuated a mouse model of multiple sclerosis
(MS). Central nervous system (CNS) CD3
+ T cell and F4/80
+ monocyte/macrophage infiltration and demyelination were
significantly reduced with hAEC treatment. Besides the known secretion of prostaglandin E2 (PGE2), we report the novel
finding that hAEC utilize transforming growth factor-b (TGF-b) for immunosuppression. Neutralization of TGF-b or PGE2 in
splenocyte proliferation assays significantly reduced hAEC-induced suppression. Splenocytes from hAEC-treated mice
showed a Th2 cytokine shift with significantly elevated IL-5 production. While transferred CFSE-labeled hAEC could be
detected in the lung, none were identified in the CNS or in lymphoid organs. This is the first report documenting the
therapeutic effect of hAEC in a MS-like model and suggest that hAEC may have potential for use as therapy for MS.
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Introduction
Multiple sclerosis (MS) is a T cell-mediated demyelinating
disease affecting over two million people worldwide with no cure
available [1,2]. Myelin oligodendrocyte glycoprotein (MOG) [3,4]
induced experimental autoimmune encephalomyelitis (EAE) is an
animal model extensively used to study the pathogenesis of MS by
inducing paralytic symptoms, and demyelination in the CNS
accompanied by perivascular mononuclear cell infiltration [5,6,7].
Mesenchymal stem (stromal) cells, which can inhibit T cell
expansion, are being trialed as a therapy for MS [8]. We explored
the potential of human amniotic epithelial cells (hAEC) to suppress
a mouse model of MOG-induced EAE. hAEC originate from
pluripotent embryonic epiblasts, express some embryonic and
mesenchymal stem cell markers [9,10,11,12], and are isolated
from the amniotic membrane of the human placenta. hAEC can
be obtained in large amounts without extended ex vivo expansion
or ethical concerns compared to bone marrow and embryo
derived stem cells. They have stem cell-like features and can
differentiate into lineages representing cells originating from the
three germ layers [10,11], and express low levels of Class IA
human leukocyte antigens (HLA) and lack Class II antigens which
may potentially reduce the risk of immune-rejection after
transplantation [10,12]. Previous studies have shown that hAEC
also have immunomodulatory properties and inhibit mixed
lymphocyte reactions and mitogen stimulated T cell proliferation
[13,14] where some of these effects may be attributed by secreted
factor(s) [15]. Besides having effect on T cells, hAEC have been
shown to secrete neurotrophic substances [16,17] suggesting that
hAEC transplantation may be useful for the treatment and repair
of inflammatory neurological diseases. Overall, the ease of
accessibility, low antigenicity, repair capacity and immunomodu-
latory properties make hAEC an important cell type for
regenerative medicine.
Here, we show that intravenous hAEC transplantation potently
ameliorated MOG-induced EAE, significantly reduced CD3
+ T
cells and F4/80
+ monocyte/macrophage infiltration and demye-
lination within the central nervous system (CNS). We also showed
that hAEC secreted transforming growth factor-b (TGF-b) and
prostaglandin E2 (PGE2) in primary culture. Blocking TGF-b
using a neutralizing antibody or PGE2 by indomethacin
significantly reduced the suppression of splenocyte proliferation
by hAEC. In addition, splenocytes from hAEC-treated mice
produced significantly more Th2 cytokine IL-5 compared to
control. Injected CFSE-labeled hAEC were detected in the lung
but none were detectable in the CNS or peripheral lymphoid
organs. We suggest that hAEC may have potential for treating MS
due to their immunosuppressive effects and improvement seen
within the CNS of the mouse model of MS.
Materials and Methods
Ethics Statement
The study was approved by Southern Health Human Research
Ethics Committee and the Institutional Review Board of Monash
University. Informed, written consent was obtained from each
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35758patient prior to amnion membrane collection. Tissues were
retrieved from placentae delivered by healthy women with a
normal singleton pregnancy undergoing elective cesarean section
at term (37–40 weeks gestation; n=30). Animal experimentation
was approved by the Animal Ethics Committee, Monash
University (approval number MMCB 2009/16).
hAEC isolation and culture
Cell isolation, culture and characterization were as described
previously [10,18]. Briefly, amnion membranes were cut into small
pieces and digested twice in 0.05% trypsin:EDTA (Gibco) for
40 min at 37uC. Following inactivation of trypsin with newborn
calf serum, dispersed cells were washed in DMEM/F12 medium
(Gibco) and erythrocytes lysed in hypotonic solution. Batches
(n=15) .99% positive for the epithelial markers cytokeratin-7
and 8/18 (Dako, Denmark) by flow cytometry and displaying a
cobblestone epithelial morphology in culture were used for in vivo
and in vitro studies [19].
EAE induction and treatment
EAE was induced in female C57BL/6 mice 8–12 weeks old by
immunization of 200 mg MOG35–55 peptide (GL Biochem, China)
and 350 ng pertussis toxin (Sigma-Aldrich) given on the day of
immunization and repeated 2 days later [7]. MOG35–55 peptide
was emulsified with 100 ml complete Freud’s antigen (CFA; Sigma-
Alderich) and 4 mg/ml Mycobacerium tuberculosis (Difco Laborato-
ries) in PBS. Two million hAEC (primary cells, passage 0, pooled
from 4 donors) in basal media were administered intravenously on
day 9 after immunization in 3 independent experiments, while
control littermates remained untreated (hAEC-treated mice,
n=25; EAE control mice, n=26, in total 3 experiments). Animals
were monitored daily and neurological impairment scored on an
arbitrary clinical score: 0, no clinical sign; 1, limp tail; 2, limp tail
and hind limb weakness; 3, severe hind limb paresis; 4, complete
hind limb paresis; 5, moribund or death [6,7]. All studies were
performed with approval of the local animal ethics committee. As
required by animal ethics, mice were euthanized upon reaching a
score of 3.
Detection of immunoregulatory molecules produced by
hAEC
hAEC (n=7 donors) were cultured for 7 days in complete
DMEM-F12 and then 2 days more in serum-deprived DMEM-
F12 medium. TGF-b1, interleukin-10 (IL-10) and hepatocyte
growth factor (HGF) were measured using ELISA kits (R&D
Systems). Nitric oxide (NO) production was detected using Griess
reagent system (Promega). PGE2 was detected by EIA kit
(Cayman Chemical). Cytokine and PGE2 measurements are
expressed as pg/ml/million hAEC.
Splenocyte suppression assays and cytokine detection
Mouse splenocytes were used as responders for mitogen/antigen
stimulation. Gamma-irradiated hAEC (20 Gy) as suppressor cells
were co-cultured at different ratios with splenocytes (5610
5) in 96-
well plates. For antigen non-specific suppression, splenocytes from
naı ¨ve mice were stimulated with the mitogen ConA (5 or 10 mg/
ml, Sigma-Aldrich). For antigen-specific suppression, splenocytes
from EAE-induced mice were stimulated with MOG35–55 peptide
(1, 10, or 100 mg/ml). Proliferation was assessed by
3H-thymidine
incorporation as described earlier [6]. Blocking assays were
performed by adding anti-human TGF-b monoclonal antibody
(0.4 mg/ml, R&D Systems) or the PGE2 inhibitor indomethacin
(1 nM, Sigma-Aldrich) to hAEC/splenocyte cultures. In some
experiments, 72 hr culture supernatants were collected for mouse
cytokine detection (IL-4, IL-5, IL-10, IL-17, IFN-c, GM-CSF,
TNF-a) by flow cytometry according to the manufacturer’s
instructions (Bender MedSystems/FlowCytomix, eBioscience).
Detection of anti-MOG antibodies
Anti-MOG antibodies were detected in mouse sera as described
previously [6]. Sera were collected from mice at the end-point of in
vivo experiments, and tested at 1:300 dilutions in 96-well plates
coated with 5 mg/ml of MOG35–55 peptide. Anti-MOG antibodies
bound to MOG were detected by horseradish-peroxidase
conjugated goat anti-mouse IgG (Dako, Denmark) and then
developed by TMB ELISA substrate (Thermo Scientific). Mean
absorbance of samples analyzed in triplicate was calculated minus
Figure 1. Dose-dependent suppression of splenocyte proliferation by hAEC. (A) ConA (5 mg/ml) stimulated proliferation of splenocytes
from naive mice was dose-dependently inhibited by hAEC in hAEC:splenocyte ratios ranging from 1:5 to 1:10240 (n=5). (B) Proliferation of
splenocytes from EAE mice stimulated by 1 mg/ml and 10 mg/ml MOG peptide was inhibited by hAEC (n=3) at hAEC:splenocyte ratios of 1:10 and
1:40. Splenocyte proliferation is expressed as counts per minute (cpm) of
3H-thymidine incorporation. All data are means6SEM.
doi:10.1371/journal.pone.0035758.g001
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Counter (Perkin-Elmer).
Flow cytometry
Cells from spleen and inguinal lymph nodes which were
harvested from hAEC-treated and EAE control mice were stained
for 30 min at 4uC with PB-, PE-, or APC-conjugated monoclonal
antibodies: CD4 (clone RM4–5, 1 mg/ml, BD), CD8 (clone 53-6.7,
1 mg/ml, BD), CD19 (clone 1D3, 0.25 mg/ml, eBioscience), CD25
(clone not specified, 1 mg/ml, BD), Foxp3 (clone FJK-16s, 1 mg/
ml, APC anti-mouse/rat staining kit, eBioscience), or matched
isotype control IgG (BD or eBioscience). The percentage of stained
cells was analyzed by CANTO flow cytometer (BD). Fc receptors
of splenocytes were blocked prior to antibody staining by anti-
mouse CD16/CD32 (clone 2.4G2, 2.5 mg/ml, BD) for at least
15 min at 4uC.
Histology
Histological assessment of spinal cord was performed as
previously described [6]. On average, 20 sections (5 mm) taken
20 mm apart from each mouse were examined. The extent of
inflammation and demyelination was evaluated blinded with
hematoxylin and eosin (H&E) and Luxol fast blue (LFB) stains,
respectively [6,7]. For inflammation, evaluation was performed
using H&E-stained sections and scored as follows: 0, no
inflammation; 1, cellular infiltrate only in the perivascular areas
and meninges; 2, mild cellular infiltrate in parenchyma; 3,
moderate cellular infiltrate in parenchyma; 4, severe cellular
infiltrate in parenchyma. Myelin breakdown was assessed as pale
staining with LFB and scored as follows: 0, no demyelination; 1,
mild demyelination; 2, moderate demyelination; 3, severe
demyelination.
For immunostaining, CNS paraffin sections (5 mm) were
dewaxed and rehydrated treated with standard antigen retrieval
Figure 2. hAEC infusion potently ameliorated EAE and reduced spinal cord pathology. EAE was induced by immunization with 200 mg
MOG35–55 peptide in 100 ml CFA followed by 350 ng pertussis toxin and the clinical scores were evaluated. (A) hAEC (2610
6) injected intravenously
on day 9 after EAE induction ameliorated disease development (n=25 in total) while control animals developed EAE (n=26 in total). Data shown are
combined results of three independent experiments each using pooled hAEC from n=4 donors. (B) Spinal cord sections were stained by H&E and
LFB for assessment of cellular infiltrates and demyelination, respectively. Representative spinal cord sections from hAEC-treated mice showed intact
myelin sheath (blue color) from LFB staining and no cellular infiltrate from H&E staining. EAE control sections show regions of demyelination (arrows)
and cellular infiltrate (arrow heads). (C) hAEC-treated mice (n=9) showed significantly lower histological scores in both H&E and LFB assessments
compared to EAE control (n=5). All data are means6SEM.
doi:10.1371/journal.pone.0035758.g002
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activity was quenched by adding 0.6% H2O2. Non-specific
binding was minimized by CAS protein blocking solution
(Invitrogen). Sections were incubated with anti-CD3 (Abcam) or
anti-F4/80 (eBioscience) antibodies. Appropriate secondary anti-
bodies were used and detected using DAB (Vector Laboratories).
Slides were counterstained with hematoxylin. Three spinal cord
sections were analyzed per mouse.
hAEC tracking
After harvesting, primary hAEC from n=4 donors were pooled
and labeled with CFSE (Invitrogen) as described previously [19].
Briefly, CFSE was dissolved in DMSO and further diluted 1000
times with DMEM-F12, then added to the hAEC suspension
(1610
6 cells/ml)at a final concentration of 10 mM. After incubation
at 37uC for 10 min, the staining was quenched by addition of 5
volumes of DMEM/F12. The CFSE-labeled hAEC were then
washed, resuspended in DMEM-F12 medium and intravenously
injected into MOG immunized mice (n=5). Each mouse received
2610
6 cells in 200 ml medium. Seven days later, mice were killed
and organs were collected. Single cells from 1/3 of each spleen and
the right inguinal lymph node were analyzed by acquiring 1.5–
2610
6 live cell events using flow cytometry while the remaining
spleens, the left inguinal lymph nodes, lungs, the livers, the brains
and spinal cords were frozen in OCT and sectioned (5 mm thick)
and examined for CFSE positive cells. Between 9–16 frozen tissue
sections were analyzed for each organ/mouse.
Statistical Analysis
Data are presented as mean6SEM and evaluated by one-way
ANOVA with Tukey’s test or Student’s T-test. A P value ,0.05
was considered significant.
Results
hAEC suppress in vitro splenocyte proliferation
Since T cell-mediated responses are thought to be crucial for MS
development, we assessed hAEC for their capacity to suppress T cell
proliferation in vitro and then assessed their potential to relieve MS-
like symptoms in a mouse model in vivo.W ef o u n dt h a th A E C
potently suppressed the proliferation of splenocytes from naive mice
stimulated with 5 mg/ml ConA. Dose-dependent suppression of
ConA stimulation of splenocytes was observed at hAEC:splenocyte
ratios ranging from 1:5 to 1:10240. Suppression of 95% was observed
at hAEC:splenocyte ratios of 1:5 and 1:10, and even at hAEC:sple-
nocyte ratio of 1:10240 suppression of 55% was still observed
(Fig. 1A). hAEC also exerted similar immunosuppressive effects in a
MOG antigen-specific setting. Splenocytes from MOG-induced
diseased mice showed vigorous proliferation to MOG peptide re-
stimulation (Fig. 1B). hAEC potently inhibited these proliferative
responses by 60–90% at hAEC:splenocyte ratios of 1:10 and 1:40 at
different MOG peptide concentrations (1 and 10 mg/ml) (Fig. 1B).
Thus, hAEC exert potent suppression of splenocyte proliferation in
both antigen non-specific and antigen-specific manner.
hAEC ameliorate EAE and improve CNS histopathology
Given the potent immunosuppressive effect of hAEC in vitro,w e
then assessed their in vivo therapeutic effects by injecting 2610
6
hAEC into mice at day 9 post-EAE induction. hAEC infusion
ameliorated EAE in mice from three independent experiments
with significance detected in mean scores after day 11 (p,0.05).
The hAEC-treated mice (n=25) had mild or delayed EAE
compared to their littermate controls (n=26, Fig. 2A).
Examination of spinal cords from hAEC-treated mice showed
no or minimal inflammatory cell infiltration and myelin loss while
Figure 3. Reduced CD3
+ T cells and F4/80
+ monocytes/macrophages in CNS. Average number of CD3
+ T cells (A) and F4/80
+ cells (B)
enumerated per spinal cord section (mean of 3 sections per mouse) showed significant reduction in hAEC-treated mice (n=8) compared to EAE
control (n=4). Photomicrographs showing representative CD3 (black arrowheads) and F4/80 (white arrowheads) staining in hAEC-treated and EAE
control spinal cords. All data are means6SEM.
doi:10.1371/journal.pone.0035758.g003
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demyelination (Fig. 2B). Blinded quantitation of these parameters
via a validated histological scoring system [6,21] showed that these
differences in cellular infiltration and demyelination were
significant (p,0.01; Fig. 2C). Inflammatory infiltrates such as T
cells and monocytes into CNS play important roles in the
pathogenesis of EAE [1,2,22]. Thus, we further investigated the
cellular infiltrate in the spinal cords for the presence of
inflammatory cells. We found significant reduction in the numbers
of CD3
+ T cells (p,0.001; Fig. 3A) and F4/80
+ monocytes/
macrophages (p=0.016; Fig. 3B) in the spinal cords from hAEC-
treated mice compared to controls.
Clinical improvement is associated with decreased
immune response to MOG and a Th2 shift
Since hAEC potently suppressed lymphocyte-mediated EAE
development, we tested whether lymphocytes from hAEC-treated
mice had reduced responsiveness to ex vivo MOG stimulation. We
found that splenocytes from hAEC-treated mice proliferated
significantly less than EAE control mice after MOG peptide
Figure 4. hAEC-treated mice showed reduced splenocyte proliferation and Th2 cytokine shift following stimulation in vitro with
MOG peptide but serum MOG antibody and lymphocyte populations in spleen and lymph nodes remained unaffected. (A)
Splenocytes from MOG-immunized and hAEC-treated mice (n=8) stimulated with MOG peptide proliferated significantly lower than EAE control mice
(n=5) at 10 and 100 mg/ml MOG peptide. ConA (10 mg/ml) stimulated proliferation from both groups was similar. (B) Cytokines in supernatants from
splenocyte cultures in (A) stimulated with 10 mg/ml of MOG for 72 hr were analyzed. IL-5 was significantly elevated. (C) MOG-specific antibodies in
sera of hAEC-treated mice (n=8) and EAE control (n=5) were not significantly different. (D) FACS analysis of T cell subsets (CD4
+, CD8
+, CD4
+CD25
+
FoxP3
+) and B cells (CD19
+) from the spleen (upper panel) and from inguinal lymph node (lower panel) showed no significant differences between
hAEC-treated mice (n=9) and EAE control (n=5). All data are means6SEM. NS: Not significant.
doi:10.1371/journal.pone.0035758.g004
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proliferation to the mitogen ConA (10 mg/ml) remained similar
(Fig. 4A). Splenocytes from hAEC-treated mice appeared to
produce less Th1 cytokine IFN-gamma and less inflammatory
cytokines GM-CSF and TNF-a; although the reduction did not
reach statistical significance (Fig. 4B). In contrast, the Th2
cytokines IL-5 and IL-10 appeared increased with the increase
in IL-5 reaching a significance of p,0.001; however, IL-4
remained unchanged. There was also no significant difference in
IL-17 levels (Fig. 4B). We also examined the effect of hAEC on B
cells by measuring anti-MOG antibody in serum from hAEC-
treated mice and from EAE control mice. hAEC treatment led to a
reduction in MOG-specific autoantibodies in sera but it failed to
reach statistical significance (Fig. 4C).
To determine whether hAEC transplantation altered the
proportion of T and B lymphocyte subpopulations in peripheral
lymphoid organs, we analyzed cells from the spleen and inguinal
lymph node by flow cytometry. We showed that there were no
significant differences in the percentages of CD4
+, CD8
+, CD19
+,
and CD4
+CD25
+FoxP3
+ [23,24,25] lymphocyte sub-populations
between hAEC-treated and the control group (Fig. 4D).
hAEC utilize TGF-b and PGE2 for immunosuppression
Soluble factors have been suggested to be utilized by hAEC
to modulate immune responses [15]. We detected TGF-b1
(86.09626.66 pg/ml/million hAEC) and PGE2 (85.336
30.55 pg/ml/million hAEC) in serum-deprived hAEC-condi-
tioned culture medium but were unable to detect HGF, NO or
IL-10. The result suggested that TGF-b and PGE2 might be
important factors produced by hAEC that suppressed the
proliferation of stimulated splenocytes. Thus, we set up two co-
culture settings using hAEC and splenocytes from EAE-diseased
mice stimulated with MOG peptide or from naı ¨ve mice stimulated
with ConA. We added neutralizing antibody to block TGF-b or
indomethacin to inhibit PGE2 in the co-culture. The presence of
TGF-b neutralizing antibody or indomethacin significantly
abrogated the inhibition of splenocyte proliferation by hAEC in
either MOG peptide or ConA-stimulated cultures (Fig. 5A, B).
Blocking of TGF-b reduced the suppressive effects on MOG-
stimulated splenocytes by nearly 75% and almost 90% on ConA-
stimulated splenocytes. Similarly, blocking of PGE2 by indometh-
acin reduced the suppression of MOG-stimulated splenocytes and
of ConA-stimulated splenocytes by approximately 20%. Thus,
these data confirmed that TGF-b and PGE2 are crucial for hAEC-
mediated suppression in vitro.
Detection of CFSE-labeled hAEC
Given the beneficial clinical outcome of hAEC infusion on EAE
development, we further investigated the possible locations of these
cells in their mouse recipient. We injected CFSE-labeled hAEC
and tracked them in peripheral organs and CNS of hAEC-treated
mice, and detected CFSE positive cells in lung tissues 7 days after
cell administration (Fig. 6). On average, 2–5 CFSE positive cells
were detected per 5 mm thick lung section. However, we failed to
detect CFSE positive cells from spleen, inguinal lymph node, liver,
brain and spinal cord sections (data not shown). In addition, flow
cytometric analysis of spleens and inguinal lymph nodes yielded
the same results as frozen sections.
Discussion
This is the first study to report the therapeutic effect of hAEC in
a mouse model of multiple sclerosis and that TGF-b is utilized by
hAEC for immunosuppression. hAEC transplantation has previ-
ously been reported to ameliorate fibrosis models in the liver and
in the lung [20,26]. These cells have also ameliorated a
Parkinson’s disease model by increased production of neurotroph-
ic factors that enhanced local repair [27]. Our study demonstrates
that hAEC have potent immunosuppressive ability both in vitro and
in vivo. In ConA-stimulated and MOG-stimulated hAEC-spleno-
cyte co-culture assays, hAEC exerted suppression in both antigen
non-specific and antigen-specific settings. Furthermore, hAEC
infusion on day 9 after EAE induction protected mice from disease
development.
We identified TGF-b and PGE2 as molecules utilized by hAEC
for immunosuppression. TGF-b, a T cell growth inhibitor which
inhibits T cell proliferation and DNA synthesis [28,29,30], is a
powerful immunosuppressive molecule. TGF-b deficient mice
suffer severe multifocal inflammatory lesions [31] while blocking
TGF-b signaling in T cells causes disruption in T cell development
and function [32]. TGF-b signaling in dendritic cells is also needed
to control autoreactive myelin-reactive T cells [33]. TGF-b is
thought to promote the resolution of inflammation with systemic
treatment suppressing CNS inflammatory lesions and signs of EAE
[34,35]. In a previous study, using human specific PCR primers
we have shown that TGF-b mRNA is expressed in lungs of hAEC-
treated mice [26], and therefore it is likely that TGF-b produced
by hAEC contributed to the improvement of EAE in the current
Figure 5. TGF-b blocking antibody and indomethacin reversed
hAEC suppression of splenocyte proliferation stimulated by
ConA and MOG peptide. hAEC:splenocyte at 1:40 ratio were co-
cultured with splenocytes from EAE mice and MOG (10 mg/ml), or with
splenocytes from naı ¨ve mice and ConA (5 mg/ml). Data shown is from
n=3 experiments each using pooled cells from n=4 donors. Addition
of TGF-b neutralizing antibody (A) or PGE2 antagonist indomethacin (B)
significantly reduced the suppression exerted by hAEC in both settings.
Data presented as percentage of suppression compared with TGF-b
neutralizing antibody or PGE2 antagonist treated control groups
(splenocytes+MOG/ConA), respectively. All data are means6SEM.
doi:10.1371/journal.pone.0035758.g005
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pressive properties including inhibition of T cell proliferation and
stimulating the production of Th2 cytokines such as IL-5 and IL-
10 [36,37]. The actions of these molecules are in agreement with
our observations that splenocytes from hAEC-treated, EAE-
protected mice, proliferated significantly less when stimulated ex
vivo with MOG, and that supernatants from these cultures revealed
a Th2 shift in their cytokine profile with significantly elevated IL-5.
Upregulation of Th2 cytokines such as IL-5 have been shown to
have a protective effect on EAE [38,39].
Multiple sclerosis and EAE are considered T cell-mediated
diseases [1,2] because adoptive transfer of CNS antigen-activated
T cells is sufficient to induce EAE [40,41]. Activation of CNS-
reactive T cells initiates local microglia expansion and recruitment
of blood-borne monocytic cells [42,43]. These cells secrete pro-
inflammatory cytokines and participate in demyelination [44].
Monocytic infiltration into the CNS is correlated with progression
of clinical disease and blocking their infiltration prevents EAE
progression [22]. Thus, the significant milder EAE and reduced
demyelination in hAEC-treated mice are in agreement with our
observations of dramatic reduction in CD3
+ T cell and F4/80
+
monocyte/macrophage infiltration in the CNS.
Taken together, our findings suggest that by producing TGF-b
and PGE2, hAEC treatment limited the expansion of MOG-
reactive T cells and their infiltration into the CNS which in turn
limited monocytic cell infiltration, and disease development. In
addition, the reported neurotrophic factors such as brain-derived
neurotrophic factor and nerve growth factor [16] produced by
hAEC may also have contributed in part to the beneficial effect in
hAEC-treated EAE mice.
We attempted to track the whereabouts of the systemic
delivered hAEC. Seven days after the injection of hAEC into
EAE-induced mice, we could only detect CFSE-labeled hAEC in
the lungs without detectable cells in CNS or peripheral lymphoid
organs. From the mesenchymal stem/stromal cell (MSC) litera-
ture, MSC were found to provide clinical benefits without their
necessary presence in the affected organs, with most of the cells
trapped within the lungs [45,46]. Instead, it is now being proposed
that MSC act from a distance by producing immunomodulatory
molecule(s) during their transient appearance after systemic
injection. Whether a similar scenario applies to hAEC awaits
further investigation.
Our study demonstrated that hAEC have potent immunosup-
pressive capacity in the murine model of MS both in vitro and in
vivo. Given the ready availability of human placenta and the ease
of hAEC isolation from this organ, we suggest that hAEC has
potential for application as cell therapy for multiple sclerosis.
However studies using fewer numbers of hAEC in the mouse
model and more information on the immunomodulative effects of
hAEC in humans should be acquired before consideration can be
given for clinical application in MS.
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